We are a development stage specialty pharmaceutical company focused on the development of late-stage (PH II and PH III) prescription drugs for gastrointestinal disorders, specifically anal fissures and fecal incontinence.

We believe that anal fissures and fecal incontinence each represent a significant unmet medical need.

Our product candidate portfolio consists of two late-stage drugs intended to treat these conditions, for which, to our knowledge, there are no currently approved prescription products in the US:

• VEN 307,Diltiazem cream, a commonly used drug used orally for hypertension and angina, formulated topically for the treatment of anal fissures, ready to enter Phase III studies
• VEN 308, Phenylephrine gel, a common ingredient in cough and cold medicines, formulated topically for the treatment of fecal incontinence ; ready to enter PH IIB studies